Pancreatic Lesions
Share this page:
CyberKnife® Radiosurgery for Pancreatic Lesions
CyberKnife® Clinical Experience
The largest CyberKnife® experience for pancreatic carcinoma patients has been gained by the Stanford group, which has applied this method as a single treatment for inoperable patients, as well as using it in conjunction with chemotherapy-intensity modulated radiotherapy in a more aggressive treatment protocol (17,18).
The Stanford single treatment CyberKnife® experience describes an impressive 100% local control and absence of serious gastrointestinal toxicity at the highest tested dose level (17). Unfortunately, the more aggressive Stanford combined chemotherapy-IMRT-CyberKnife® regimen (18) did not meaningfully improve the survival result compared with historical controls (9-12), and did result in a greater incidence of serious gastrointestinal toxicity compared with their single treatment CyberKnife® regimen.
Pancreatic Carcinoma
Written by Donald B. Fuller, M.D. – Radiation Oncologist